{
    "clinical_study": {
        "@rank": "161718", 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine the efficacy, safety, and tolerability\n      of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks\n      in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase\n      III study."
        }, 
        "brief_title": "Study Evaluating Venlafaxine ER in Adults With Panic Disorder", 
        "completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "condition": "Panic Disorder", 
        "condition_browse": {
            "mesh_term": "Panic Disorder"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A male or female outpatient\n\n          -  Be at least 18 years of age and legal age of consent\n\n          -  Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months\n             before study day 1\n\n        Exclusion Criteria:\n\n          -  Treatment with venlafaxine (IR or ER) within 6 months of study day 1\n\n          -  Known hypersensitivity to venlafaxine (IR or ER) or related compounds\n\n          -  History or presence of any clinically important hepatic, renal, or other medical\n             disease that might compromise the study or be detrimental to the patient (eg,\n             clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal\n             cell epithelioma], uncontrolled hypertension)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "343", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 5, 2002", 
        "id_info": {
            "nct_id": "NCT00038896", 
            "org_study_id": "0600B5-353"
        }, 
        "intervention": {
            "intervention_name": "Venlafaxine ER", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Venlafaxine"
        }, 
        "keyword": [
            "Panic", 
            "Disorder"
        ], 
        "lastchanged_date": "August 13, 2009", 
        "official_title": "A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder", 
        "overall_official": {
            "affiliation": "Wyeth is now a wholly owned subsidiary of Pfizer", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038896"
        }, 
        "source": "Wyeth is now a wholly owned subsidiary of Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2009"
    }, 
    "geocoordinates": {}
}